Skip to main content

Belen Garcia Prats

My name is Belén Garcia Prats, I hold a Bachelor’s Degree in Biomedical Sciences. Currently, I am the in vivo laboratory technician at Drug Delivery and Targeting (DDT) group at VHIR, holding more than one year experience working with oncologic mouse models in an ISO900 environment.

Institutions of which they are part

Research technician
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Belen Garcia Prats

Institutions of which they are part

Research technician
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

My name is Belén Garcia Prats, I hold a Bachelor’s Degree in Biomedical Sciences. Currently, I am the in vivo laboratory technician at Drug Delivery and Targeting (DDT) group at VHIR, holding more than one year experience working with oncologic mouse models in an ISO900 environment.

My name is Belén Garcia Prats, I hold a Bachelor’s Degree in Biomedical Sciences and I obtained in 2020 a MSc in Molecular Biotechnology. Hence, I am passionate about biomedical research areas such as pharmacology and toxicology, cancer biology and molecular techniques.
My previous experience encompasses working in a clinical laboratory, being in charge of the realization of biochemical and immunological analysis on clinical simples. In addition, I was parto f a basic research group, where I worked with cell cultures for the study of type 2 diabetes mellitus pathogenesis.
Currently, I am the in vivo laboratory technician at Drug Delivery and Targeting (DDT) group at VHIR. I have obtained the laboratory animals handling accreditation, holding more than one year experience working with oncologic mouse models in an ISO900 environment.

Projects

Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT)

IP: Ibane Abasolo Olaortua
Collaborators: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Maria Francesca Cortese, Sandra Mancilla Zamora
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 01173
Duration: 01/01/2022 - 30/06/2025

Impacto y valor pronóstico de vesículas extracelulares tumorales provenientes de células madre cancerígenas en tumores de mama triple negativo.

IP: Joaquin Seras Franzoso
Collaborators: Laura García Latorre, Diego Baranda Martínez-Abasca, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Belen Garcia Prats
Funding agency: Instituto de Salud Carlos III
Funding: 99220
Reference: PI22/01301
Duration: 01/01/2023 - 31/12/2025

Evolvable platform for designing cancer treatment strategies using nanoparticles (EVO-NANO)

IP: Ibane Abasolo Olaortua
Collaborators: Joaquin Seras Franzoso, Simon Schwartz Navarro, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Belen Garcia Prats
Funding agency: EUROPEAN COMMISSION
Funding: 568847.5
Reference: EVO-NANO_H2020FETOPEN2017
Duration: 01/10/2018 - 31/03/2022

SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH..

IP: Ibane Abasolo Olaortua
Collaborators: Marc Miquel Moltó Abad, Olga Sánchez- Maroto Carrizo, Julia German Cortes, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Belen Garcia Prats, Angels Alcina Mila, SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH.., Maria Fidel Lledò, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Simon Schwartz Navarro
Funding agency: EUROPEAN COMMISSION
Funding: 649580
Reference: SAFE-N-MEDTECHEC_H2020-NMBP2018
Duration: 01/04/2019 - 30/09/2023

Related news

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Related professionals

Javier Francisco Ramon Pasías

Javier Francisco Ramon Pasías

Postdoctoral researcher
Neuromuscular and Mitochondrial Pathology
Read more
Maria Garcia Carrasco

Maria Garcia Carrasco

Reconstructive Surgery of the Locomotor System
Read more
Laia Closa Gil

Laia Closa Gil

Postdoctoral researcher
Transfusional Medicine
Read more
Rebeca Murillo Torres

Rebeca Murillo Torres

Research technician
Head and Neck Cancer: Biomedical Research Cancer Stem cells
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.